TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35386419

Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulation (VNS) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-implantation EEG analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical model for prediction of response to VNS therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantification of differences in EEG power spectra
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical classifier for VNS response
Number of subjects: 0
Study: 35386497

Group type: EXPERIMENTAL
Intervention: Preconception hemoglobin A1c levels
Number of subjects: 1194
Study: 35386499

Group type: EXPERIMENTAL
Intervention: Controlled slow freezing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncontrolled Slow Freezing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitrification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 35386508

Group type: EXPERIMENTAL
Intervention: hs-CRP levels 1-3 mg/L
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: hs-CRP levels >3-10 mg/L
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: hs-CRP levels >10 mg/L
Number of subjects: 781

Group type: COMPARATOR
Intervention: hs-CRP levels <1 mg/L
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Baseline body mass index adjustment
Number of subjects: 781
Study: 35386606

Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg once weekly for 10 weeks (increased to 180 mg once weekly if inadequate response)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 2 weeks (initial tolerance assessment)
Number of subjects: 16
Study: 35387272

Group type: EXPERIMENTAL
Intervention: Chewing tapioca pearls in bubble tea drinks
Number of subjects: 0
Study: 35387414

Group type: EXPERIMENTAL
Intervention: Preoperative Stereotactic Body Radiation Therapy (SBRT) - 35 to 40 Gy in 5 fractions every other day
Number of subjects: 16
Study: 35387421

Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation (60 Gy in 30 fractions for PET responders)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation (74 Gy in 30 fractions for nonresponders)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation
Number of subjects: 45
Study: 35387433

Group type: EXPERIMENTAL
Intervention: Smartphone-coupled wristband monitoring system with a photo plethysmography (PPG) sensor and telecare analytic service
Number of subjects: 0
Study: 35387482

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity (MHO)
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: Obesity with unhealthy metabolic profile
Number of subjects: 1730

Group type: EXPERIMENTAL
Intervention: MHO
Number of subjects: 1730
Study: 35387488

Group type: EXPERIMENTAL
Intervention: V937 (Coxsackievirus A21)
Number of subjects: 0
Study: 35387589

Group type: EXPERIMENTAL
Intervention: Cognitive task while sitting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perturbed walking
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perturbed walking with a concurrent cognitive task
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dual-task conditions (perturbed walking with cognitive task)
Number of subjects: 20
Study: 35387627

Group type: EXPERIMENTAL
Intervention: High HDI countries
Number of subjects: 2522

Group type: COMPARATOR
Intervention: Very high HDI countries
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: Black ethnicity
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: Other ethnicity
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: White/Caucasian ethnicity
Number of subjects: 2522
Study: 35387647

Group type: EXPERIMENTAL
Intervention: Sumadhur intervention (group-based household-level intervention for 4 months)
Number of subjects: 200
Study: 35387780

Group type: EXPERIMENTAL
Intervention: AZD8701 (FOXP3 antisense oligonucleotide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surrogate murine FOXP3 ASO
Number of subjects: 0
Study: 35387811

Group type: COMPARATOR
Intervention: Apolipoprotein CIII (ApoCIII), Apolipoprotein E (ApoE), A-2-macroglobulin (A2M), complement C3 (C3), complement factor H (FH) levels in patients with amnestic mild cognitive impairment (aMCI)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Complement C3 levels in patients with Alzheimer's disease (AD)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Discriminant analysis including all protein markers, age, sex, genotype and education level
Number of subjects: 416
Study: 35387820

Group type: EXPERIMENTAL
Intervention: Caesarean section (CS)
Number of subjects: 77242
Study: 35387847

Group type: EXPERIMENTAL
Intervention: Incremental Step Test (IST)
Number of subjects: 50
Study: 35387874

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35388003

Group type: EXPERIMENTAL
Intervention: Ramucirumab (an anti-VEGFR2 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study: 35388340

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessments (EMA) regarding location, social context, and eating and drinking
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Social context of eating and drinking
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Location of eating (home vs work)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 6-month weight change
Number of subjects: 209
Study: 35388352

Group type: EXPERIMENTAL
Intervention: Implantable Collamer Lens (ICL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acrylic Implantable Phakic Contact Lens (IPCL)
Number of subjects: 60
Study: 35388792

Group type: EXPERIMENTAL
Intervention: Interdisciplinary Health in work program
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Monodisciplinary inclusive work measures (treatment as usual)
Number of subjects: 1383
Study: 35388996

Group type: COMPARATOR
Intervention: Culprit-only PCI
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Angiography-guided CR
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: FFR-guided CR
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Angiography-guided PCI
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: FFR-guided strategy
Number of subjects: 13
Study: 35389070

Group type: EXPERIMENTAL
Intervention: EMI-137 (0.13 mg/kg)
Number of subjects: 19
Study: 35389110

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 84

Group type: COMPARATOR
Intervention: CT
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MRI with DWIBS
Number of subjects: 84
Study: 35389356

Group type: EXPERIMENTAL
Intervention: InvolveMe intervention (digital communication intervention)
Number of subjects: 23
Study: 35389756

Group type: EXPERIMENTAL
Intervention: hs-cTnT (hs-cTnT-Elecsys)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: hs-cTnI assays (hs-cTnI-Architect, hs-cTnI-Access, hs-cTnI-Vista)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control subjects without SMD presenting with adjudicated noncardiac chest pain (n=3508)
Number of subjects: 211
Study: 35389891

Group type: EXPERIMENTAL
Intervention: High ApoE-HDL-C group
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Low ApoE-HDL-C group
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Low ApoE-HDL-C
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: ApoC-III in HDL
Number of subjects: 795
Study: 35390135

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 53
Study: 35390146

Group type: EXPERIMENTAL
Intervention: Monoclonal gammopathy of undetermined significance (MGUS)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis (CH)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis (CH) in patients with MGUS
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Monoclonal gammopathy of undetermined significance (MGUS) in patients with CH
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Correlation between MGUS and CH
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Clinical and laboratory covariates
Number of subjects: 777
Study: 35390177

Group type: EXPERIMENTAL
Intervention: Different medical interventions (e.g., nasal saline irrigations, corticosteroids, antibiotics, dornase alfa, CFTR modulators)
Number of subjects: 0
Study: 35390178

Group type: EXPERIMENTAL
Intervention: Enpatoran (dual TLR 7 and TLR 8 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic/pharmacodynamic (PopPK/PD) model-based simulations
Number of subjects: 0
Study: 35390233

Group type: EXPERIMENTAL
Intervention: Mental health screening using smartphones
Number of subjects: 0
Study: 35390452

Group type: EXPERIMENTAL
Intervention: rFVIIIFc (efmoroctocog alfa, Elocta®/Eloctate®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (damoctocog alfa pegol, Jivi®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAX 855 (rurioctocog alfa pegol, Adynovate®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol, Esperoct®)
Number of subjects: 0
Study: 35391576

Group type: EXPERIMENTAL
Intervention: Maintaining accurate prognostic awareness
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Gaining accurate prognostic awareness
Number of subjects: 334

Group type: COMPARATOR
Intervention: Maintaining inaccurate/unknown prognostic awareness
Number of subjects: 334

Group type: COMPARATOR
Intervention: Intensive care unit care
Number of subjects: 334

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 334

Group type: COMPARATOR
Intervention: Chemotherapy/immunotherapy
Number of subjects: 334
Study: 35391631

Group type: EXPERIMENTAL
Intervention: hCG trigger
Number of subjects: 11
Study: 35391774

Group type: EXPERIMENTAL
Intervention: Deep learning model for automated total kidney volume (TKV) measurement on T2-weighted MRI studies.
Number of subjects: 129
Study: 35391785

Group type: EXPERIMENTAL
Intervention: Enriched virtual reality (VR) executive function training (EFT) combined with exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise-only intervention
Number of subjects: 30
Study: 35391840

Group type: EXPERIMENTAL
Intervention: CT-FFR derived from coronary computed tomography angiography (CTA) using a new computational fluid dynamics (CFD) algorithm
Number of subjects: 317

Group type: COMPARATOR
Intervention: CTA
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: CT-FFR in gray zone lesions
Number of subjects: 317
Study: 35391843

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 0
Study: 35387272

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35392613

Group type: EXPERIMENTAL
Intervention: Haploidentical donor (HID) HSCT
Number of subjects: 289
Study: 35392744

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily
Number of subjects: 7368

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 7368
Study: 35392873

Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation programmes (IRP) activities
Number of subjects: 146
Study: 35392968

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) program, 3 sessions per week for 3 weeks
Number of subjects: 14
Study: 35393018

Group type: EXPERIMENTAL
Intervention: Midregional pro-atrial natriuretic peptide (MR-proANP)
Number of subjects: 1759
Study: 35393106

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1492
Study: 35393247

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and gemcitabine
Number of subjects: 37
Study: 35393269

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 1401
Study: 35393266

Group type: EXPERIMENTAL
Intervention: Optimal weight loss (OWL) group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Suboptimal weight loss (SWL) group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Weight regain (WR) group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: No weight regain (NWR) group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: SWL group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: OWL group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: WR group
Number of subjects: 75
Study: 35393312

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) programme
Number of subjects: 148

Group type: COMPARATOR
Intervention: Before ERAS programme implementation (control group)
Number of subjects: 148
Study: 35393313

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proprioceptive modifications and cognitive biases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning curve
Number of subjects: 0
Study: 35393338

Group type: EXPERIMENTAL
Intervention: eCLIPs bifurcation remodelling system in conjunction with coils
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: eCLIPs bifurcation remodelling system
Number of subjects: 20
Study: 35393403

Group type: EXPERIMENTAL
Intervention: Gene dosage disorders (GDDs)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Reference idiopathic autism spectrum disorder (ASD)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Typically developing control (TD)
Number of subjects: 350
Study: 35393425

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m²)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Berzosertib
Number of subjects: 47
Study: 35393942

Group type: EXPERIMENTAL
Intervention: Online group CBT-M (16 hours in 16 weeks) with standard psychiatric care
Number of subjects: 156

Group type: COMPARATOR
Intervention: In-office group CBT-M with standard psychiatric care
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Online group CBT-M
Number of subjects: 156

Group type: COMPARATOR
Intervention: In-office group CBT-M
Number of subjects: 156
Study: 35394152

Group type: EXPERIMENTAL
Intervention: Yttrium-90 glass microspheres
Number of subjects: 209
Study: 35394255

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus 5-fluorouracil and cisplatin (PPF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil and cisplatin (PF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil and cisplatin (PF) for esophageal squamous cell carcinoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil and cisplatin (PF) with PD-L1 CPS ≥ 10
Number of subjects: 0
Study: 35394445

Group type: EXPERIMENTAL
Intervention: Tablet computer-based remote patient monitoring system
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Implementation framework for digital health technology
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Preimplementation assessment of ICU's need for innovation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ongoing evaluation of implementation conditions
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Involvement of all stakeholders and transparent communication
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Defined leadership roles
Number of subjects: 7
Study: 35394449

Group type: EXPERIMENTAL
Intervention: Rapid Antigen Tests (RATs)
Number of subjects: 704

Group type: COMPARATOR
Intervention: RT-PCR
Number of subjects: 704
Study: 35394527

Group type: EXPERIMENTAL
Intervention: EDWARDS INTUITY Elite aortic valve system
Number of subjects: 276
Study: 35394583

Group type: EXPERIMENTAL
Intervention: Wrist-worn photoplethysmography (PPG) monitor
Number of subjects: 31
Study: 35394598

Group type: EXPERIMENTAL
Intervention: Field-based outreach conducted by two local community-based organizations (CBOs) delivering the intervention
Number of subjects: 778

Group type: COMPARATOR
Intervention: Online recruitment coordinated by the trial's academic research partner
Number of subjects: 778

Group type: COMPARATOR
Intervention: Online recruitment
Number of subjects: 778
Study: 35395437

Group type: EXPERIMENTAL
Intervention: Dithiothreitol (DTT)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Sonication
Number of subjects: 187
Study: 35395574

Group type: EXPERIMENTAL
Intervention: Nurses' pain assessment before analgesic consumption
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nurses' pain assessment 1 hour after analgesic consumption
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Agreement between children's and nurses' pain scores before analgesic consumption
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Agreement between children's and nurses' pain scores 1 hour after analgesic consumption
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Agreement between children's and parents' pain scores before analgesic consumption
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Agreement between children's and parents' pain scores 1 hour after analgesic consumption
Number of subjects: 47
Study: 35395680

Group type: EXPERIMENTAL
Intervention: Entrectinib (oral, once-daily)
Number of subjects: 43
Study: 35395811

Group type: EXPERIMENTAL
Intervention: Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (CLARO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Collaborative care (general)
Number of subjects: 0
Study: 35396138

Group type: EXPERIMENTAL
Intervention: PDR-/HDR-brachytherapy alone with 86-90 Gy (EQD2, α/β = 3 Gy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PDR-/HDR-brachytherapy as boost after external beam radiation therapy up to a total dose of 91-96 Gy (EQD2, α/β = 3 Gy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PDR-/HDR-brachytherapy with simultaneous integrated focal boost to intra-prostatic tumor lesions up to a total dose of 108-119 Gy (EQD2, α/β = 3 Gy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PDR-/HDR-brachytherapy with simultaneous integrated focal boost
Number of subjects: 101
Study: 35396177

Group type: EXPERIMENTAL
Intervention: 6-minute stepper test (6MST)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: sit-to-stand test (STST)
Number of subjects: 118
Study: 35396282

Group type: COMPARATOR
Intervention: Medical Treatment (MT)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 971
Study: 35396296

Group type: EXPERIMENTAL
Intervention: WHO Standards-based online questionnaire
Number of subjects: 600
Study: 35396312

Group type: EXPERIMENTAL
Intervention: Co-creation of a health plan and support via a digital platform
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Digital platform support
Number of subjects: 19
Study: 35396316

Group type: EXPERIMENTAL
Intervention: Advanced MRI techniques (Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours and Luminal Water imaging)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histological analysis from biopsy or prostatectomy
Number of subjects: 0
Study: 35396812

Group type: EXPERIMENTAL
Intervention: Talazoparib 250mcg daily with carboplatin AUC5-6 and paclitaxel 80 mg/m²
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Talazoparib 250mcg on a 3- or 7-day schedule with carboplatin AUC6 and paclitaxel 80 mg/m²
Number of subjects: 43
Study: 35396980

Group type: EXPERIMENTAL
Intervention: Secondary findings (SF) offered as part of clinical exome sequencing (ES)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Hypothetical categories of secondary findings (H-SF)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Declining secondary findings (SF)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Reasons for accepting SF
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Reasons for declining SF
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Hesitancy about receiving secondary findings
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Communication approaches regarding SF decisions
Number of subjects: 190
Study: 35397092

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 and 2 weeks
Number of subjects: 0
Study: 35397434

Group type: EXPERIMENTAL
Intervention: Gatipotuzumab (1400 mg every 2 weeks) combined with tomuzotuximab (1200 mg every 2 weeks)
Number of subjects: 52
Study: 35397574

Group type: EXPERIMENTAL
Intervention: WALK-Cph intervention
Number of subjects: 48
Study: 35397575

Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oncology care
Number of subjects: 0
Study: 35397804

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy at 40 Gy in 15 fractions or 42.72 Gy in 16 fractions followed by skin-sparing mastectomy and DIEP flap reconstruction
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy followed by skin-sparing mastectomy and DIEP flap reconstruction
Number of subjects: 33
Study: 35397828

Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 16
Study: 35397952

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus docetaxel and prednisone
Number of subjects: 104
Study: 35398007

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 35398201

Group type: EXPERIMENTAL
Intervention: Highlanders with chronic mountain sickness (CMS+)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Highlanders without chronic mountain sickness (CMS-)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Highlanders (CMS+ and CMS-)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lowlanders
Number of subjects: 30
Study: 35398584

Group type: EXPERIMENTAL
Intervention: Trial of labor after cesarean delivery of nonvertex second twins
Number of subjects: 236

Group type: COMPARATOR
Intervention: Trial of labor after cesarean delivery of vertex second twins
Number of subjects: 236